Acusphere submits NDA for Imagify

Ultrasound contrast developer Acusphere has submitted a new drug application (NDA) to the U.S. Food and Drug Administration for its Imagify ultrasound contrast agent.

Imagify is designed to assess myocardial perfusion, according to the Watertown, MA-based firm.

Related Reading

Acusphere cuts annual net loss, March 17, 2008

Acusphere gets Nasdaq warning letter, January 14, 2008

Acusphere reports Q3 results, November 9, 2007

Acusphere releases Imagify study data, November 6, 2007

Acusphere names new CFO, October 4, 2007

Copyright © 2008

Page 1 of 509
Next Page